Background And Purpose: Recent data have indicated that α3β4* neuronal nicotinic (n) ACh receptors may play a role in morphine dependence. Here we investigated if nACh receptors modulate morphine physical withdrawal.

Experimental Approaches: To assess the role of α3β4* nACh receptors in morphine withdrawal, we used a genetic correlation approach using publically available datasets within the GeneNetwork web resource, genetic knockout and pharmacological tools. Male and female European-American (n = 2772) and African-American (n = 1309) subjects from the Study of Addiction: Genetics and Environment dataset were assessed for possible associations of polymorphisms in the 15q25 gene cluster and opioid dependence.

Key Results: BXD recombinant mouse lines demonstrated an increased expression of α3, β4 and α5 nACh receptor mRNA in the forebrain and midbrain, which significantly correlated with increased defecation in mice undergoing morphine withdrawal. Mice overexpressing the gene cluster CHRNA5/A3/B4 exhibited increased somatic signs of withdrawal. Furthermore, α5 and β4 nACh receptor knockout mice expressed decreased somatic withdrawal signs compared with their wild-type counterparts. Moreover, selective α3β4* nACh receptor antagonists, α-conotoxin AuIB and AT-1001, attenuated somatic signs of morphine withdrawal in a dose-related manner. In addition, two human datasets revealed a protective role for variants in the CHRNA3 gene, which codes for the α3 nACh receptor subunit, in opioid dependence and withdrawal. In contrast, we found that the α4β2* nACh receptor subtype is not involved in morphine somatic withdrawal signs.

Conclusion And Implications: Overall, our findings suggest an important role for the α3β4* nACh receptor subtype in morphine physical dependence.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128047PMC
http://dx.doi.org/10.1111/bph.12741DOI Listing

Publication Analysis

Top Keywords

nach receptor
24
receptor subtype
12
α3β4* nach
12
morphine withdrawal
12
nicotinic ach
8
physical dependence
8
morphine
8
nach
8
nach receptors
8
morphine physical
8

Similar Publications

This article provides a comprehensive overview of the current treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) following the failure of first-line therapy. Although significant progress has been made in the primary treatment of hormone-sensitive prostate cancer, the management of mCRPC remains a clinical challenge. The article outlines the diagnostic criteria for mCRPC, which can be confirmed through biochemical progression and imaging techniques.

View Article and Find Full Text PDF
Article Synopsis
  • A meta-analysis was conducted to compare the effectiveness of sacubitril-valsartan (S/V) versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in preventing recurrent atrial fibrillation (AF) after catheter ablation.
  • The study included four clinical trials with 642 total patients, showing that the S/V group had a significantly lower rate of persistent AF (RR: 0.54) and a reduction in left atrial volume compared to the ACEI/ARB group.
  • While S/V appears more effective in reducing AF recurrence, the left ventricular ejection fraction did not differ significantly between the two treatments, highlighting the need for
View Article and Find Full Text PDF

[Hand-foot syndrome after taking fibroblast growth factor receptor 2 inhibitor].

Dermatologie (Heidelb)

October 2024

Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München, LMU München, Frauenlobstr. 9-11, 80337, München, Deutschland.

View Article and Find Full Text PDF

Objectives: Neurological disorders represent a significant global health challenge, necessitating the exploration of novel therapeutic agents. Apigenin, a natural flavonoid abundantly found in various plants, has garnered attention for its potential neuroprotective properties. In this study, we employed molecular docking simulations to investigate the interaction between apigenin and key molecular targets associated with neurological disorders.

View Article and Find Full Text PDF

Galantamine suppresses α-synuclein aggregation by inducing autophagy via the activation of α nicotinic acetylcholine receptors.

J Pharmacol Sci

October 2024

Pharmacology and Neurobiology Laboratory, College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577, Japan. Electronic address:

Article Synopsis
  • Synucleinopathies like Parkinson's disease and dementia involve problems in the brain caused by a protein called α-synuclein.
  • Currently, there are no effective treatments for these disorders, but researchers found that a drug called galantamine might help by preventing harmful protein buildup.
  • Studies showed that galantamine could protect brain cells and stop the spread of α-synuclein in mice, which means it could be a promising new treatment option.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!